ASH 2022 | Considering patient preference when selecting between continuous and time-limited therapy in CLL
Jennifer Woyach, MD, Ohio State University College of Medicine, Columbus, OH, discusses how patient preference may influence treatment choice in chronic lymphocytic leukemia (CLL). In high-risk patients, it appears that continuous treatment with a BTK inhibitor is the optimal approach. However, for most patients continuous versus fixed-duration treatment is dependent on patient preference. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Karyopharm Therapeutics: Research Funding; Schrodinger: Research Funding; Newave: Consultancy; Genentech: Consultancy; Pharmacyclics: Consultancy; ArQule: Consultancy; MorphoSys: Consultancy, Research Funding; Loxo@Lilly: Research Funding; AbbVie: Consultancy, Research Funding; Janssen: Consultancy; BeiGene: Consultancy; AstraZeneca: Consultancy.
